Bristol-Myers Squibb first one fourth net sales increase 5 percent to $3.S drug information . Regulatory approval for YERVOY. The business confirmed guidance for the entire year also. The effectiveness of our economic and R&D functionality in the first one fourth confirms our ability to execute our concentrated BioPharma strategy and helps position us for long-term achievement, said Lamberto Andreotti, ceo, Bristol-Myers Squibb. Our string of achievements in the one fourth is a great start to an exciting year in which we are anticipating several essential regulatory decisions and the demonstration of essential data across our portfolio.
The ability to rapidly investigate the clinical utility of Bristol-Myers Squibb’s Immuno-Oncology brokers, as single brokers or in combinations, including with therapies from other sources, is a robust accelerant to our programs. The focus on malignancies that are usually relatively under-investigated in therapeutic conditions is particularly important and satisfying for all involved in this collaboration, stated Francis J. Giles, M.D., director of the NMDTI and deputy director of the Lurie Cancer tumor Center. Immuno-Oncology is an innovative approach to cancer analysis and treatment that’s designed to harness the body’s own disease fighting capability to fight tumor.